|1.||Corot, Claire: 12 articles (12/2013 - 05/2002)|
|2.||Gillard, Jonathan H: 11 articles (11/2013 - 07/2004)|
|3.||Graves, Martin J: 10 articles (11/2013 - 07/2004)|
|4.||Daldrup-Link, Heike E: 9 articles (01/2015 - 06/2002)|
|5.||Howarth, Simon P S: 9 articles (11/2013 - 09/2006)|
|6.||Robinson, Simon P: 9 articles (10/2012 - 04/2003)|
|7.||Barentsz, Jelle O: 8 articles (12/2013 - 11/2004)|
|8.||Robert, Philippe: 8 articles (12/2013 - 08/2006)|
|9.||Tang, Tjun Y: 8 articles (11/2013 - 01/2007)|
|10.||Gillard, J H: 8 articles (02/2011 - 08/2007)|
09/19/2008 - "Furthermore, SM-USPIO was demonstrated to be able to selectively accumulate in the tumor cells, resulting in a marked decrease of MRI T2-weighted signal intensity. "
07/01/2009 - "USPIO administration significantly enhanced visualization of tumor microvascularity on gradient echo 8 T MRI and significantly improved visualization of tumor microvascularity. "
11/01/2003 - "Compared with gadopentetate, the new blood pool agent feruglose provided an improved characterization of the evaluated breast lesions; however, at the cost of weaker overall tumor enhancement."
01/01/2010 - "Following the submission of this article to Cancer Imaging, unfortunately the European manufacturer of ferumoxtran-10 (Guerbet) has withdrawn the product pending further phase III studies. "
09/19/2008 - "The in vivo study in the ch-hep-3 tumor-bearing nude mice indicated that MRI using the SM-USPIO as contrast agent possessed good diagnostic ability, suggesting that SM-USPIO had the potential to be a promising targeted contrast agent for diagnosis of HCC."
|2.||Neoplasm Metastasis (Metastasis)
09/01/2003 - "To determine the safety and efficacy of ferumoxtran 10-enhanced magnetic resonance (MR) imaging for diagnosis of metastases to lymph nodes and the clinical usefulness of ferumoxtran 10 in nodal staging. "
01/01/2014 - "In this study, we evaluated the feasibility of detecting lymph node metastasis using a new ultrasmall superparamagnetic iron oxide particle, PJY10, in a rabbit model. "
11/01/2011 - "After a systematic review of the studies, sensitivity, specificity, the Q* value and other measures of accuracy of USPIO-enhanced MRI in the diagnosis of lymph-node metastases were summarized. "
09/01/2007 - "Diagnostic performance was compared using size criteria (metastasis was defined when short axis diameter >5 or >10mm) or morphologic criteria on conventional MRI, the combined study of USPIO precontrast and postcontrast images, and USPIO postcontrast study alone. "
09/01/2003 - "Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study."
06/02/2009 - "Aggressive lipid-lowering therapy over a 3-month period is associated with significant reduction in USPIO-defined inflammation. "
06/02/2009 - "A significant reduction from baseline in USPIO-defined inflammation was observed in the 80-mg group at both 6 weeks (DeltaSI 0.13; p = 0.0003) and at 12 weeks (DeltaSI 0.20; p < 0.0001). "
06/01/2009 - "The aim of this study was to explore whether there is a difference in the degree of MR defined inflammation using USPIO particles, between symptomatic and asymptomatic carotid plaques. "
04/01/2009 - "In this study, we aimed to explore USPIO as a marker for the more diffuse inflammation in MS NAWM, using quantitative MRI. "
06/01/2013 - "(18)F-FDG-PET seems to be more sensitive than USPIO P904 to detect early changes in plaque inflammation."
|4.||Head and Neck Neoplasms (Head and Neck Cancer)
09/01/2005 - "This study confirms the efficacy of MRI with USPIO in patients with head and neck cancer. "
07/01/2006 - "USPIO-enhanced magnetic resonance imaging for nodal staging in patients with head and neck cancer."
08/01/2003 - "These techniques include dynamic contrast-enhanced MR imaging for evaluating soft tissue masses and cervical lymph nodes, the use of ultrasmall superparamagnetic iron oxide contrast agent, and functional techniques such as in vivo and in vitro MR spectroscopy of head and neck cancer and lymph nodes and apparent diffusion coefficient mapping of parotid glands. "
05/01/2004 - "[Use of ultrasmall ferric oxide (Sinerem) particles as a magnetic resonance contrast substance for imaging lymph nodal metastases in cancer of the head and neck]."
07/01/2006 - "To determine the accuracy of ultrasmall superparamagnetic iron oxide (USPIO)-enhanced magnetic resonance imaging (MRI) for nodal staging in patients with head and neck cancer. "
|5.||Atherosclerotic Plaque (Atheroma)
09/01/2015 - "MRI study of atherosclerotic plaque progression using ultrasmall superparamagnetic iron oxide in Watanabe heritable hyperlipidemic rabbits."
04/01/2014 - "A functionalized USPIO-based negative contrast material was used in this study, demonstrating feasibility of sensitive MRI-based detection of atherosclerotic plaque formation in the carotid arteries and in the renal cortex, paving the way to potential future clinical applications."
04/01/2005 - "These data suggest that the exposure period of atherosclerotic plaque to USPIO rather than the kinetics of the USPIO uptake by plaque alone is a critical criterion for experimental design of in vivo studies."
09/01/2015 - "USPIO-enhanced MRI visualized the accumulation of macrophages in early atherosclerotic plaques of WHHL rabbits in the course of natural progression."
08/01/2014 - "[Ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance angiography combined with inflammatory factors for detecting atherosclerotic plaques in rabbits]."
|1.||ferumoxtran-10 (ultrasmall superparamagnetic iron oxide)
|2.||ferric oxide (iron oxide)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
|4.||Lymph Node Excision (Lymph Node Dissection)